Syndax Pharmaceuticals will release its Q1 2026 financial results and host a conference call on April 30, 2026.
Quiver AI Summary
Syndax Pharmaceuticals announced it will release its financial results for the first quarter of 2026 and provide a business update on April 30, 2026. The company will host a conference call and audio webcast at 4:30 p.m. ET that day, which can be accessed via their website or through designated phone numbers. For those unable to attend, a replay will be available on their website 24 hours after the call for 90 days. Syndax, focused on innovative cancer therapies, highlights its pipeline including FDA-approved treatments like Revuforj® and Niktimvo™. Further details are accessible on the company's website and social media platforms.
Potential Positives
- Announcement of first quarter 2026 financial results and business update scheduled for April 30, 2026, signaling transparency and engagement with investors.
- Management's live conference call and audio webcast provide an opportunity for direct communication with stakeholders, enhancing investor relations.
- Highlights of FDA-approved therapies in the pipeline, showcasing the company's innovative approach in advancing cancer treatments.
Potential Negatives
- None
FAQ
When will Syndax Pharmaceuticals announce its Q1 2026 financial results?
Syndax Pharmaceuticals will announce its Q1 2026 financial results on April 30, 2026.
How can I access the Syndax conference call?
You can access the conference call by dialing 800-590-8290 for domestic calls or 240-690-8800 for international calls.
Where can I find the live webcast for the earnings release?
The live webcast can be accessed through the Events & Presentations page in the Investors section of Syndax's website.
Will there be a replay available for the conference call?
Yes, a replay will be available on the Investors section of the Syndax website approximately 24 hours after the call.
What are some key products in Syndax's pipeline?
Key products include Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr), both of which are FDA-approved cancer therapies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SNDX Insider Trading Activity
$SNDX insiders have traded $SNDX stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $SNDX stock by insiders over the last 6 months:
- MICHAEL A METZGER (Chief Executive Officer) has made 0 purchases and 2 sales selling 24,571 shares for an estimated $513,654.
- KEITH A. GOLDAN (Chief Financial Officer) has made 0 purchases and 2 sales selling 5,492 shares for an estimated $114,636.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SNDX Hedge Fund Activity
We have seen 107 institutional investors add shares of $SNDX stock to their portfolio, and 111 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HOOD RIVER CAPITAL MANAGEMENT LLC added 2,316,553 shares (+inf%) to their portfolio in Q4 2025, for an estimated $48,670,778
- VANGUARD GROUP INC added 1,091,717 shares (+21.2%) to their portfolio in Q4 2025, for an estimated $22,936,974
- BANK OF AMERICA CORP /DE/ added 1,012,993 shares (+27.4%) to their portfolio in Q4 2025, for an estimated $21,282,982
- MILLENNIUM MANAGEMENT LLC removed 994,519 shares (-95.0%) from their portfolio in Q4 2025, for an estimated $20,894,844
- UBS GROUP AG removed 958,294 shares (-57.2%) from their portfolio in Q4 2025, for an estimated $20,133,756
- QUBE RESEARCH & TECHNOLOGIES LTD removed 956,707 shares (-58.2%) from their portfolio in Q4 2025, for an estimated $20,100,414
- ENSIGN PEAK ADVISORS, INC added 789,480 shares (+97.6%) to their portfolio in Q4 2025, for an estimated $16,586,974
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SNDX Analyst Ratings
Wall Street analysts have issued reports on $SNDX in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 12/09/2025
- Barclays issued a "Overweight" rating on 11/24/2025
- HC Wainwright & Co. issued a "Buy" rating on 10/27/2025
To track analyst ratings and price targets for $SNDX, check out Quiver Quantitative's $SNDX forecast page.
$SNDX Price Targets
Multiple analysts have issued price targets for $SNDX recently. We have seen 11 analysts offer price targets for $SNDX in the last 6 months, with a median target of $40.0.
Here are some recent targets:
- Corinne Johnson from Goldman Sachs set a target price of $34.0 on 04/01/2026
- Salim Syed from Mizuho set a target price of $43.0 on 03/31/2026
- Faisal Khurshid from Jefferies set a target price of $40.0 on 03/30/2026
- Anupam Rama from JP Morgan set a target price of $45.0 on 03/09/2026
- Yigal Nochomovitz from Citigroup set a target price of $57.0 on 03/02/2026
- Justin Zelin from BTIG set a target price of $56.0 on 12/09/2025
- Etzer Darout from Barclays set a target price of $35.0 on 11/24/2025
Full Release
NEW YORK, April 24, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, April 30, 2026.
In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, April 30, 2026.
The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:
Conference ID: Syndax1Q26
Domestic Dial-in Number: 800-590-8290
International Dial-in Number: 240-690-8800
Live webcast:
https://sndx-1q26.open-exchange.net
For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj
®
(revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit
www.syndax.com/
or follow the Company on
X
and
LinkedIn
.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
[email protected]
Tel 781.684.9827
SNDX-G
